Numerate Forms Drug Discovery Collaboration with Merck & Co., Inc. to Utilize Numerate’s In Silico Drug Design Technology

Published: Mar 14, 2012

SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that it has entered into a research collaboration with Merck, through a subsidiary. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed cardiovascular disease target.

Back to news